Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

Thymulin Analog (PAT)vsThymalin

Synthetic thymulin-derived nonapeptide with potent analgesic and anti-inflammatory properties

Russian thymic peptide complex that rejuvenates immune function and supports healthy aging

Healing & RecoveryImmune

At a Glance

Quick
comparison

Dose Range

Thymulin Analog (PAT)

1 mcg–50 mcg mcg

Thymalin

5–10 mg

Frequency

Thymulin Analog (PAT)

Once daily

Thymalin

Once daily

Administration

Thymulin Analog (PAT)

Intraperitoneal injection

Thymalin

Intramuscular injection

Cycle Length

Thymulin Analog (PAT)

Ongoing/indefinite

Thymalin

4-6 weeks

Onset Speed

Thymulin Analog (PAT)

Moderate (1-2 weeks)

Thymalin

Moderate (1-2 weeks)

Evidence Level

Thymulin Analog (PAT)

Strong human trials (Phase 3 or FDA approved)

Thymalin

Limited human trials

Efficacy

Benefit
ratings

Thymulin Analog (PAT)
Thymalin

Pain Relief

Thymulin Analog (PAT)88%
Thymalin0%

Anti-Inflammatory

Thymulin Analog (PAT)90%
Thymalin0%

Neuroprotection

Thymulin Analog (PAT)78%
Thymalin0%

Immune Restoration

Thymulin Analog (PAT)0%
Thymalin88%

Longevity Support

Thymulin Analog (PAT)0%
Thymalin82%

Disease Prevention

Thymulin Analog (PAT)0%
Thymalin78%

Technical Data

Compound
specifications

Thymulin Analog (PAT)

Molecular Formula

C37H62N12O15

Molecular Weight

858.9 Da

Half-Life

Effects peak at 1-2 hours; diminish by 3-4 hours post-single dose

Bioavailability

Effective via intraperitoneal and intracerebroventricular routes in preclinical models

CAS Number

Not assigned

Thymalin

Molecular Formula

Complex mixture; active dipeptide EW: C16H19N3O5

Molecular Weight

Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da

Half-Life

Not precisely characterized for complex; immune effects persist weeks post-administration

Bioavailability

High via intramuscular or subcutaneous injection

CAS Number

63958-90-7

Protocols

Dosing
tiers

Thymulin Analog (PAT)

Thymalin

starting

5 mg daily

Once daily

5 days

Initial dose to assess tolerance and immune response; best for first-time users

standard

10 mg daily

Once daily

10 days

Standard clinical protocol used in most Russian research studies; most effective dose

advanced

10 mg Thymalin + 5 mg Epitalon daily

Once daily

20 days, repeated every 6 months

Combined peptide protocol for enhanced longevity and geroprotective effects

Applications

Best
suited for

Thymulin Analog (PAT)

Neuropathic pain research

Thymulin Analog (PAT) is particularly well-suited for individuals focused on neuropathic pain research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Anti-inflammatory therapy development

Thymulin Analog (PAT) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Novel analgesic mechanism investigation

Thymulin Analog (PAT) is particularly well-suited for individuals focused on novel analgesic mechanism investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Cytokine-mediated pain pathway studies

Thymulin Analog (PAT) is particularly well-suited for individuals focused on cytokine-mediated pain pathway studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymalin

Aging Adults Seeking Immune Support

Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.

Longevity and Anti-Aging Protocols

Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.

Seasonal Illness Prevention

Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.

Safety Profile

Side
effects

Thymulin Analog (PAT)

Common

  • Injection Site Reaction
  • Transient Immune Modulation
  • Mild Sedation
  • Short Duration of Action

Uncommon

  • Potential Immune Suppression
  • CNS Effects with Central Administration

Serious

  • Unintended Immune Stimulation

Thymalin

Common

  • No side effects in most patients
  • Mild injection site reaction

Uncommon

  • Transient low-grade fever
  • Mild flu-like symptoms
  • Temporary headache

Serious

  • Severe allergic reaction

Research Status

Safety
& evidence

Thymulin Analog (PAT)

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

Research compound

Safety Overview

Thymulin Analog (PAT) is a synthetic 9-amino acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is a research compound ONLY—NOT approved for human use. No serious adverse effects have been documented in extensive preclinical studies spanning 17+ years. However, this is a critical limitation: all data comes from animal models (primarily rats and mice). Zero completed human clinical trials exist. The peptide has not undergone human Phase 1 safety testing. No manufactured batches meet pharmaceutical standards. PAT's primary mechanism—alpha-7 nAChR potentiation—could theoretically affect multiple organ systems, but human safety data is absent. As an immune-modulating compound, prolonged high-dose use could theoretically suppress protective immunity, though animal studies show no adverse effects at therapeutic doses. Individual responses in humans are completely unknown.

Contraindications

  • xNot approved for human use
  • xPotential immune modulation concerns with chronic use
  • xUnknown drug-drug interactions
  • xPregnancy and lactation (insufficient safety data)

Thymalin

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.

Contraindications

  • xActive thymic tumors or malignancies
  • xKnown hypersensitivity to animal-derived peptide products
  • xPregnancy and breastfeeding (insufficient safety data)
  • xSevere uncontrolled autoimmune disease without medical supervision

Decision Guide

Which is
right for you?

Choose Thymulin Analog (PAT) if...

  • Neuropathic pain research
  • Anti-inflammatory therapy development
  • Novel analgesic mechanism investigation
  • Cytokine-mediated pain pathway studies

Choose Thymalin if...

  • Immune system restoration in aging adults
  • Longevity and healthy aging support
  • Reducing infection frequency and severity
  • Multi-system health optimization
Thymulin Analog (PAT) vs Thymalin — Peptide Comparison | Peptide Initiative